Skip to contentA
Axim Biotechnologies, Inc.
A
AXIMAxim Biotechnologies, Inc. Q2 2016 · 10-Q
Revenue$11.24K$11.24K−7.2% vs Q2 2015 Net Income-$1.89M-$1.89MN/M vs Q2 2015 EPS Diluted-$0.05-$0.05N/M vs Q2 2015 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Axim Biotechnologies, Inc. · CIK 1514946 · Engraved from SEC EDGAR
Operating Cash Flowderived-$352,357N/M Margins · derivedGross margin-7.5%−107.5 pt vs Q2 2015
Operating margin-4372.3%+8511.7 pt vs Q2 2015
Net margin-16800.7%−3915.3 pt vs Q2 2015
ended Jun 30, 2016 · filed Aug 22, 2016 · 53 d after period end